Winton Group LTD Seagen Inc. Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $211,810 - $239,072	1,106 New	1,106 $234,000
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $403,694 - $642,545	-3,164 Reduced 26.2%	8,914 $1.8 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $727,459 - $862,575	6,198 Added 105.41%	12,078 $1.55 Million
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $197,764 - $263,320	-1,462 Reduced 19.91%	5,880 $805,000
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $200,754 - $330,863	1,845 Added 33.56%	7,342 $1.3 Million
Q1 2022 May 11, 2022	BUY	$119.61 - $157.85 $657,496 - $867,701	5,497 New	5,497 $792,000
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $394,206 - $527,727	-2,765 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$142.45 - $169.82 $393,874 - $469,552	2,765 New	2,765 $469,000
Q2 2021 Aug 10, 2021	SELL	$135.08 - $161.1 $349,451 - $416,765	-2,587 Closed	0 $0
Q1 2021 Jul 21, 2021	SELL	$137.51 - $190.8 $1,512 - $2,098	-11 Reduced 0.42%	2,587 $359,000
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $427,708 - $550,594	2,598 New	2,598 $455,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.